| Literature DB >> 24940400 |
Yu-Xi Jia1, Jin-Ran Li2, Cui-Ying Mao1, Wei-Tian Yin1, Ri-Hua Jiang3.
Abstract
Glycyrrhizin has a role in immune regulation in the central nervous system, but its impact on sciatic nerve injury had not previously been reported. In this study, a BALB/c mouse model of sciatic nerve injury was used to explore the role of glycyrrhizin in sciatic nerve repair and its underlying mechanism. Glycyrrhizin with intragastric gavage of 10 and 20 mg/kg weight per day (mid- and high-dose, respectively) inhibited p75 neurotrophin receptor (p75NTR) expression at the protein and mRNA levels versus the 5 mg/kg (low-dose) group and control (0.9% NaCl solution) at one, two, four and eight weeks following sciatic nerve injury, and simultaneously improved the action potential amplitude and motor nerve conductive velocity. Combined Marsland, Glees and Erikson's silver stain and Luxol fast blue staining results indicated that high- and mid-dose glycyrrhizin promoted improved sciatic nerve myelination compared with the low-dose or control groups eight weeks after injury. Immunofluorescence staining demonstrated that glycyrrhizin had an inhibitory effect to a certain degree on local hypertrophic scar and inflammatory responses in the mouse model. In conclusion, glycyrrhizin can promote sciatic nerve regeneration and functional repair, in which doses of 10 and 20 mg/kg per day are more effective than lower doses, and such regeneration is associated with the downregulation of p75NTR.Entities:
Keywords: glycyrrhizin; p75 neurotrophin receptor; peripheral nerve injury; regeneration; sciatic nerve
Year: 2014 PMID: 24940400 PMCID: PMC3991491 DOI: 10.3892/etm.2014.1546
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Figure 1Structural formula of glycyrrhizin.
Neuroelectrophysiological potential amplitude (mV) and MNCV (m/sec) of each dose group at each time-point following injury (n=10).
| Glycyrrhizin, mg/kg/day | Action potential amplitude, mV | MNCV, m/sec | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| 1 week | 2 weeks | 4 weeks | 8 weeks | 1 week | 2 weeks | 4 weeks | 8 weeks | |
| 20 (High) | 2.32±0.21 | 4.64±0.17 | 26.13±0.16 | 26.44±0.68 | 20.8±0.31 | 41.9±0.59 | 64.8±1.73 | 68.8±1.34 |
| 10 (Mid) | 2.29±0.16 | 4.39±0.19 | 21.87±0.26 | 23.11±0.33 | 19.6±0.38 | 35.5±0.72 | 55.7±1.33 | 60.4±0.61 |
| 5 (Low) | 1.40±0.13 | 2.66±0.07 | 17.56±0.32 | 19.76±0.36 | 13.0±0.19 | 30.6±0.84 | 52.0±0.66 | 55.6±0.43 |
| 0 (Control) | 1.31±0.10 | 2.19±0.15 | 13.29±0.06 | 15.77±0.68 | 10.4±0.17 | 27.6±0.48 | 49.1±0.34 | 46.9±2.17 |
P<0.05 vs. low-dose and control groups (Student’s t-test).
Values are presented as the mean ± standard deviation. MNCV, motor conductive nerve velocity.
Figure 2p75NTR protein blots and relative p75NTR/GAPDH mRNA levels in high- (H), mid- (M) and low-dose (L) and control (C) groups at the time-points of one, two, four and eight weeks after injury. *P<0.05 vs. high- and mid-dose groups (Student’s t-test). Values are presented as the mean ± standard deviation, n=5. p75NTR, p75 neurotrophin receptor; GAPDH, glyceraldehyde-phosphate dehydrogenase.
Relative grayscale of p75NTR/GAPDH blots (n=5) of each dose group at each time-point following injury.
| Relative grayscale | ||||
|---|---|---|---|---|
|
| ||||
| Glycyrrhizin, mg/kg/day | 1 week | 2 weeks | 4 weeks | 8 weeks |
| 20 (High) | 0.512±0.020 | 1.088±0.022 | 0.697±0.032 | 0.233±0.025 |
| 10 (Mid) | 0.599±0.026 | 1.207±0.022 | 0.758±0.033 | 0.232±0.019 |
| 5 (Low) | 0.874±0.021 | 1.333±0.022 | 1.111±0.020 | 0.288±0.030 |
| 0 (Control) | 1.311±0.035 | 1.735±0.24 | 1.432±0.013 | 0.523±0.004 |
P<0.05 vs. low-dose and control groups;
P<0.05 vs. control group (Student’s t-test).
Values are presented as the mean ± standard deviation. p75NTR, p75 neurotrophin receptor; GAPDH, glyceraldehyde-phosphate dehydrogenase.
Figure 3Stained transverse slices eight weeks after injury. (A) Combined Marsland, Glees and Erikson’s silver stain and Laxol fast blue staining (light microscopy, ×400). Nerve fibers are stained black and myelin is stained blue. (B) Indirect immunoflurescence staining of astrocytes detected by confocal laser scanning microscopy. Glial fibrillary acidic protein (GFAP) staining appears as blue dots and neuron-specific enolase (NSE) staining appears as an abundance of green in the cytoplasm. (a) High-dose group, (b) mid-dose group, (c) low-dose group, (d) control.
Myelinated fiber status and immunofluorescence intensity eight weeks after injury (n=5).
| Glycyrrhizin, mg/kg/day | Myelinated fiber count, n/mm2 | Myelinated fiber diameter, μm | GFAP fluorescence intensity (a.u.) | NSE fluorescence intensity (a.u.) |
|---|---|---|---|---|
| 20 (High) | 76±3 | 2.46±0.30 | 133.21±24.18 | 466.26±23.12 |
| 10 (Middle) | 70±1 | 2.30±0.17 | 222.88±21.32 | 298.48±32.77 |
| 5 (Low) | 55±3 | 1.96±0.31 | 246.39±15.88 | 288.02±30.15 |
| 0 (Control) | 49±1 | 1.56±0.25 | 299.74±17.31 | 178.71±15.13 |
P<0.05 vs. low-dose and control groups;
P<0.05 vs. control group (Student’s t-test).
Values are presented as the mean ± standard deviation. GFAP, glial fibrillary acidic protein; NSE, neuron-specific enolase.